Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain inhibitory neurons; strongest in somatotrophs | 0.75 |
| chemistry Open Targets | compounds already reach it: soticlestat | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 16 Parkinson's papers of 299 | 0.63 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 3354
Sealed predictions
- CYP46A1 in dopamine neurons, braak-0.47 (p 0.197) → -0.05 (p 0.893)receipt 3361
Swarm cases
receipt 3361: CYP46A1 in dopamine neurons, braak
- power
- full sample -0.25 (p 0.319, n 18), 95% CI -0.64 to +0.25. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.31 (p 0.218, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.39 (p 0.114, n 18). could be the mix.
- skeptic
- leave-one-out range -0.41 to -0.15, sign flips 0; without severely affected donors -0.25 (p 0.319, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CYP46A1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts